Bayer has found a buyer for its hypogonadism drug Nebido but is keeping it in Germany as Grünenthal picks up its global rights for 500 million euros ($500 million). The treatment, which is the lone ...

Nebido is administered as a long-acting depot injection of testosterone undecanoate by physicians every ten to 14 weeks. Credit: Roman Chekhovskoi / Shutterstock.com. · Hospital Management · Roman ...

Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...

"Testosterone deficiency affects one in six men over 50 years 1; representing a significant burden," said Gabriel Baertschi, CEO Grünenthal. "With the completion of this deal, we can now work to bring ...

TORONTO and AACHEN, Germany, Feb. 5, 2026 /CNW/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, ...

LEXINGTON, Mass., June 4 -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV - News) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the NDA ...

Shares of Indevus Pharmaceuticals Inc. plunged nearly 70 percent after the company reported at least a two-year setback for Nebido, its three-month formulation of testosterone, for male hypogonadism ...

Grünenthal acquires Nebidofrom Bayer AG for up to 500 million. The product is expected to add about 100 million to Grünenthals EBITDA in 2023. Nebido is the gold standard for the treatment of male ...

Indevus will pay $30 million for US rights to Schering's Nebido, a testosterone-replacement injection that lasts for three months. The money includes up-front, regulatory milestone, and ...

Indevus Pharmaceuticals Inc. gained U.S. rights to Nebido, an injectable treatment for hypogonadism developed and previously launched in Europe by Berlin-based Schering AG. Terms call for Indevus to ...

Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism. This ...

BERLIN, July 14 (Reuters) - Bayer (BAYGn.DE), opens new tab is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 ...